Skip to main content
SpringerLink
Log in
Book cover

Arzneiverordnungs-Report 2013 pp 753–763Cite as

Muskelrelaxantien

  • Chapter

Zusammenfassung

Therapeutisch werden peripher und zentral wirkende Muskelrelaxantien unterschieden. Während peripher wirkende Muskelrelaxantien vor allem zur Muskelrelaxation bei Narkose eingesetzt werden, kommen zentral wirkende Muskelrelaxantien überwiegend bei der Behandlung krankhafter Tonuserhöhungen der Skelettmuskulatur zur Anwendung.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Bundesinstitut für Arzneimittel und Medizinprodukte, Auswertung der Spontanmeldungen zu Tolperison (UAW-Datenbank des BfArM), Schreiben vom 10. Mai 2011.

    Google Scholar 

  • Cardoso E, Rodrigues B, Lucena R, Oliveira IR, Pedreira G, Melo A (2005): Botulinum toxin type A for the treatment of the upper limb spasticity after stroke: a meta-analysis. Arq Neuropsiquiatr 63: 30–33.

    Article  PubMed  Google Scholar 

  • Chou R, Peterson K, Helfand M (2004): Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage 28: 140–175.

    Article  PubMed  CAS  Google Scholar 

  • Costa J, Espírito-Santo CC, Borges AA, Ferreira J, Coelho MM, Moore P, Sampaio C (2004): Botulinum toxin type A therapy for blepharospasm. Cochrane Database of Systematic Reviews 2004, Issue 2. Art. No.: CD004900. DOI: 10.1002/14651858. CD004900.pub2.

    Google Scholar 

  • Costa J, Espírito-Santo CC, Borges AA, Ferreira J, Coelho MM, Moore P, Sampaio C (2005a): Botulinum toxin type A therapy for cervical dystonia. Cochrane Database of Systematic Reviews 2005, Issue 1. Art. No.: CD003633. DOI: 10.1002/14651858. CD003633.pub2.

    Google Scholar 

  • Costa J, Espírito-Santo CC, Borges AA, Ferreira J, Coelho MM, Moore P, Sampaio C (2005b): Botulinum toxin type A therapy for hemifacial spasm. Cochrane Database of Systematic Reviews 2005, Issue 1. Art. No.: CD004899. DOI: 10.1002/14651858. CD004899.pub2.

    Google Scholar 

  • Deutsche Gesellschaft für Neurologie (2012): Leitlinie Therapie des spastischen Syndroms. www.dgn.org/component/content/article/45-leitlinien-der-dgn-2012/2431-ll-89-2012-therapie-des-spastischen-syndroms.html?q=spastikLetzterZugriff16.Mai2013.

  • Dulin J, Kovács L, Ramm S, Horvath F, Ebeling L, Kohnen R (1998): Evaluation of sedative effects of single and repeated doses of 50 mg and 150 mg tolperisone hydrochloride. Results of a prospective, ran-domized, double-blind, placebo-controlled trial. Pharmacopsychiatry. 31: 137–142.

    Article  PubMed  CAS  Google Scholar 

  • Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D (2011): Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database of Systematic Reviews 2011, Issue 12. Art. No.: CD005493. DOI: 10.1002/14651858.CD005493. pub3.

    Google Scholar 

  • Elia AE, Filippini G, Calandrella D, Albanese A (2009): Botulinum neurotoxins for poststroke spasticity in adults: a systematic review. Mov Disord 24: 801–812.

    Article  PubMed  Google Scholar 

  • European Medicines Agency (2009): Questions and answers on the referral for Myderison tablets containing tolperisone hydrochloride 50 and 150 mg. Internet: www.ema.europa.eu/pdfs/human/referral/myderison/ha_281118q&a.pdf , letzter Zugriff 16. Mai 2013.

  • European Medicines Agency (2013a): Recommendation to suspend tetrazepam-containing medicines endorsed by CMDh: 29 April 2013 EMA/256383/2013.

    Google Scholar 

  • European Medicines Agency (2013b): Questions and answers on the review of tolperisonecontaining medicines. Outcome of a procedure under Article 31 of Directive 2001/83/ EC as amended. 21 January 2013 EMA/673365/2012 rev.1 EMEA/H/ A-31/1311.

    Google Scholar 

  • Fricke U, Günther J, Zawinell A, Zeidan R (2013): Anatomisch-therapeutisch-chemische Klassifikation mit Tagesdosen für den deutschen Arzneimittelmarkt. Methodik der ATC-Klassifikation und DDD-Festlegung. WIdO GKV-Arzneimittelindex. Internet: www.wido.de/arz_atcddd-klassifi.html.

  • Gemeinsamer Bundesausschuss (2012): Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a SGB V – Fampridin vom 2. August 2012. Internet: www.g-ba.de/downloads/39-261-1541/2012-08-02_AM-RL-XII_Fampridin_BAnz.pdf.

  • GKV-Spitzenverband, Biogen Idec GmbH (2013): AMNOG-Verhandlungen für MS-Therapeutikum erfolgreich beendet. Gemeinsame Pressemitteilung – Berlin, 01.03.2013. Internet: www.gkv-spitzenverband.de/media/dokumente/presse/pressemitteilungen/2013/Gem_PM_2013-03-01_AMNOG_Fampridin.pdf.

  • Hoare BJ, Wallen MA, Imms C, Villanueva E, Rawicki HB, Carey L (2010): Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE). Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003469. DOI: 10.1002/14651858.CD003469.pub4.

    Google Scholar 

  • Infomed (2003): Anaphylaktische Reaktionen unter Tolperison (Mydocalm®) vom 27. Oktober 2003 www.infomed.ch/bdn.php?bdnid=185, Letzter Zugriff 16. Mai 2013.

  • Jackson JL, Kuriyama A, Hayashino Y (2012): Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis. JAMA 307: 1736– 1745.

    Article  PubMed  CAS  Google Scholar 

  • Keane RE, Simiand J, Morre M, Biziere K (1988a): Tetrazepam: a benzodiazepine which dissociates sedation from other benzodiazepine activities. I. Psychopharmacological profile in rodents. J Pharmacol Exp Ther 245: 692–698.

    CAS  Google Scholar 

  • Keane RE, Bachy A, Morre M, Biziere K (1988b): Tetrazepam: a benzodiazepine which dissociates sedation from other benzodiazepine activities. II. In vitro and in vivo interactions with benzodiazepine binding sites. J Pharmacol Exp Ther 245: 699–705.

    CAS  Google Scholar 

  • Kirschner J, Berweck S, Mall V, Korinthenberg R, Heinen F (2001): Botulinumtoxin – Neue Therapieoption für Kinder mit Zerebralparese. Dtsch Ärztebl 98: A3375–A3379.

    Google Scholar 

  • Programm für Nationale VersorgungsLeitlinien (2011): Nationale VersorgungsLeitlinie Kreuzschmerz. Langfassung: Internet: www.versorgungsleitlinien.de/themen/kreuzschmerz/pdf/nvl_kreuzschmerz_lang.pdf.

  • Quasthoff S, Möckel C, Zieglgänsberger W, Schreibmayer W (2008): Tolperisone: A typical representative of a class of centrally acting muscle Relexnants with less sedative side effects. CNS Neurol Therap 14: 107–119.

    Article  CAS  Google Scholar 

  • Shakespeare DT, Boggild M, Young C (2003): Anti-spasticity agents for multiple sclerosis. Cochrane Database of Systematic Reviews 2003, Issue 4. Art. No.: CD001332. DOI: 10.1002/14651858.CD001332.

    Google Scholar 

  • Simiand J, Keane PE, Biziere K, Soubrie P (1989): Comparative study in mice of tetrazepam and other centrally active skeletal muscle relaxants. Arch Int Pharmacodyn Ther 297: 272–285.

    PubMed  CAS  Google Scholar 

  • van Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM (2003): Muscle relaxants for non-specific low-back pain. Cochrane Database of Systematic Reviews 2003, Issue 4. Art. No.: CD004252. DOI: 10.1002/14651858.CD004252.

    Google Scholar 

  • Waelbroeck M, Camus J, Tastenoy M, Lambrecht G, Mutschler E, Kropfgans M et al (1993): Thermodynamics of antagonist binding to rat muscarinic M2 receptors: antimuscarinics of the pridinol, sila-pridinol, diphenidol and sila-diphenidol type. Br J Pharmacol 109: 360–370.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. PharmaFacts, Gesellschaft zur Forschung und Beratung im Bereich Arzneimittelversorgung mbH, Freiburg, Wilhelmstraße 1e, 79098

    Dr. rer. nat. Judith Günther

Authors
  1. Dr. rer. nat. Judith Günther
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. AOK NORDWEST Die Gesundheitskasse, Edisonstraße 70, 24145, Kiel

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin, Heidelberg

About this chapter

Cite this chapter

Günther, J. (2013). Muskelrelaxantien. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2013. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-37124-0_35

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-37124-0_35

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-37123-3

  • Online ISBN: 978-3-642-37124-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation